{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:38:26Z","timestamp":1789720706351,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,8,2]],"date-time":"2013-08-02T00:00:00Z","timestamp":1375401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,8,2]],"date-time":"2013-08-02T00:00:00Z","timestamp":1375401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Angiogenesis"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s10456-013-9376-3","type":"journal-article","created":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T07:52:57Z","timestamp":1375343577000},"page":"37-50","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer"],"prefix":"10.1007","volume":"17","author":[{"given":"Jing","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiansha","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,2]]},"reference":[{"issue":"28","key":"9376_CR1","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.1200\/JCO.2008.16.1612","volume":"26","author":"BP Schneider","year":"2008","unstructured":"Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD, ECOG 2100 (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26(28):4672\u20134678","journal-title":"J Clin Oncol"},{"issue":"1","key":"9376_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccr.2008.12.004","volume":"15","author":"Y Crawford","year":"2009","unstructured":"Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, Kaminker J, Ferrara N (2009) PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15(1):21\u201334","journal-title":"Cancer Cell"},{"issue":"9","key":"9376_CR3","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1158\/0008-5472.CAN-07-5271","volume":"68","author":"M Maguire","year":"2008","unstructured":"Maguire M, Nield PC, Devling T, Jenkins RE, Park BK, Pola\u0144ski R, Vlatkovi\u0107 N, Boyd MT (2008) MDM2 regulates dihydrofolate reductase activity through monoubiquitination. Cancer Res 68(9):3232\u20133242","journal-title":"Cancer Res"},{"issue":"1","key":"9376_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/modpathol.3800484","volume":"19","author":"DA Turbin","year":"2006","unstructured":"Turbin DA, Cheang MC, Bajdik CD, Gelmon KA, Yorida E, De Luca A, Nielsen TO, Huntsman DG, Gilks CB (2006) MDM2 protein expression is a negative prognostic marker in breast carcinoma. Mod Pathol 19(1):69\u201374","journal-title":"Mod Pathol"},{"issue":"2","key":"9376_CR5","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1158\/0008-5472.CAN-06-4738","volume":"68","author":"VA Carroll","year":"2008","unstructured":"Carroll VA, Ashcroft M (2008) Regulation of angiogenic factors by HDM2 in renal cell carcinoma. Cancer Res 68(2):545\u2013552","journal-title":"Cancer Res"},{"issue":"1","key":"9376_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2174\/1568009053332618","volume":"5","author":"Z Zhang","year":"2005","unstructured":"Zhang Z, Zhang R (2005) p53-independent activities of MDM2 and their relevance to cancer therapy. Curr Cancer Drug Targets 5(1):9\u201320","journal-title":"Curr Cancer Drug Targets"},{"issue":"6","key":"9376_CR7","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S0959-8049(02)00007-2","volume":"38","author":"R Mathew","year":"2002","unstructured":"Mathew R, Arora S, Khanna R, Mathur M, Shukla NK, Ralhan R (2002) Alterations in p53 and pRb pathways and their prognostic significance in oesophageal cancer. Eur J Cancer 38(6):832\u2013841","journal-title":"Eur J Cancer"},{"issue":"7","key":"9376_CR8","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/0092-8674(92)90644-R","volume":"69","author":"J Momand","year":"1992","unstructured":"Momand J, Zambetti GP, Olson DC, George D, Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69(7):1237\u20131245","journal-title":"Cell"},{"issue":"5","key":"9376_CR9","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ccr.2009.03.002","volume":"15","author":"L Gu","year":"2009","unstructured":"Gu L, Zhu N, Zhang H, Durden DL, Feng Y, Zhou M (2009) Regulation of XIAP translation and induction by MDM2 following irradiation. Cancer Cell 15(5):363\u2013375","journal-title":"Cancer Cell"},{"issue":"24","key":"9376_CR10","doi-asserted-by":"publisher","first-page":"4928","DOI":"10.1128\/MCB.06085-11","volume":"31","author":"S Zhou","year":"2011","unstructured":"Zhou S, Gu L, He J, Zhang H, Zhou M (2011) MDM2 regulates vascular endothelial growth factor mRNA stabilization in hypoxia. Mol Cell Biol 31(24):4928\u20134937","journal-title":"Mol Cell Biol"},{"issue":"12","key":"9376_CR11","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1158\/0008-5472.CAN-03-3038","volume":"64","author":"L Zhang","year":"2004","unstructured":"Zhang L, Hill RP (2004) Hypoxia enhances metastatic efficiency by up-regulating Mdm2 in KHT cells and increasing resistance to apoptosis. Cancer Res 64(12):4180\u20134189","journal-title":"Cancer Res"},{"issue":"5","key":"9376_CR12","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/S0002-9440(10)65729-X","volume":"153","author":"C Zietz","year":"1998","unstructured":"Zietz C, R\u00f6ssle M, Haas C, Sendelhofert A, Hirschmann A, St\u00fcrzl M, L\u00f6hrs U (1998) MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol 153(5):1425\u20131433","journal-title":"Am J Pathol"},{"issue":"1","key":"9376_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.molmed.2006.11.002","volume":"13","author":"LT Vassilev","year":"2007","unstructured":"Vassilev LT (2007) MDM2 inhibitors for cancer therapy. Trends Mol Med 13(1):23\u201331","journal-title":"Trends Mol Med"},{"issue":"3","key":"9376_CR14","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1158\/1078-0432.CCR-08-0399","volume":"15","author":"Y Tabe","year":"2009","unstructured":"Tabe Y, Sebasigari D, Jin L, Rudelius M, Davies-Hill T, Miyake K, Miida T, Pittaluga S, Raffeld M (2009) MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Clin Cancer Res 15(3):933\u2013942","journal-title":"Clin Cancer Res"},{"issue":"4","key":"9376_CR15","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/leu.2008.11","volume":"22","author":"L Gu","year":"2008","unstructured":"Gu L, Zhu N, Findley HW, Zhou M (2008) MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2. Leukemia 22(4):730\u2013739","journal-title":"Leukemia"},{"issue":"1","key":"9376_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2174\/1568009053332663","volume":"5","author":"R Zhang","year":"2005","unstructured":"Zhang R, Wang H, Agrawal S (2005) Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms. Curr Cancer Drug Targets 5(1):43\u201349","journal-title":"Curr Cancer Drug Targets"},{"issue":"4","key":"9376_CR17","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1158\/1078-0432.CCR-0245-03","volume":"10","author":"Z Zhang","year":"2004","unstructured":"Zhang Z, Wang H, Prasad G, Li M, Yu D, Bonner JA, Agrawal S, Zhang R (2004) Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clin Cancer Res 10(4):1263\u20131273","journal-title":"Clin Cancer Res"},{"issue":"11","key":"9376_CR18","first-page":"3613","volume":"7","author":"H Wang","year":"2001","unstructured":"Wang H, Nan L, Yu D, Agrawal S, Zhang R (2001) Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin Cancer Res 7(11):3613\u20133624","journal-title":"Clin Cancer Res"},{"issue":"11","key":"9376_CR19","doi-asserted-by":"publisher","first-page":"936","DOI":"10.4161\/cbt.9.11.11882","volume":"9","author":"MN Saha","year":"2010","unstructured":"Saha MN, Jiang H, Jayakar J, Reece D, Branch DR, Chang H (2010) MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity. Cancer Biol Ther 9(11):936\u2013944","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"9376_CR20","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1073\/pnas.94.6.2620","volume":"94","author":"S Agrawal","year":"1997","unstructured":"Agrawal S, Jiang Z, Zhao Q, Shaw D, Cai Q, Roskey A, Channavajjala L, Saxinger C, Zhang R (1997) Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc Natl Acad Sci USA 94(6):2620\u20132625","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5659","key":"9376_CR21","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1126\/science.1092472","volume":"303","author":"LT Vassilev","year":"2004","unstructured":"Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303(5659):844\u2013848","journal-title":"Science"},{"issue":"22","key":"9376_CR22","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1093\/jnci\/djp355","volume":"101","author":"T Van Maerken","year":"2009","unstructured":"Van Maerken T, Ferdinande L, Taildeman J, Lambertz I, Yigit N, Vercruysse L, Rihani A, Michaelis M, Cinatl J Jr, Cuvelier CA, Marine JC, De Paepe A, Bracke M, Speleman F, Vandesompele J (2009) Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. J Natl Cancer Inst 101(22):1562\u20131574","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"9376_CR23","doi-asserted-by":"publisher","first-page":"4858","DOI":"10.1158\/1078-0432.CCR-03-0497","volume":"10","author":"R Bianco","year":"2004","unstructured":"Bianco R, Caputo R, Caputo R, Damiano V, De Placido S, Ficorella C, Agrawal S, Bianco AR, Ciardiello F, Tortora G (2004) Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer. Clin Cancer Res 10(14):4858\u20134864","journal-title":"Clin Cancer Res"},{"issue":"4","key":"9376_CR24","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4):402\u2013408","journal-title":"Methods"},{"issue":"6","key":"9376_CR25","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1158\/1535-7163.MCT-10-1090","volume":"10","author":"T Van Maerken","year":"2011","unstructured":"Van Maerken T, Rihani A, Dreidax D, De Clercq S, Yigit N, Marine JC, Westermann F, De Paepe A, Vandesompele J, Speleman F (2011) Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3. Mol Cancer Ther 10(6):983\u2013993","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"9376_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0959-437X(01)00264-7","volume":"12","author":"D Michael","year":"2002","unstructured":"Michael D, Oren M (2002) The p53 and Mdm2 families in cancer. Curr Opin Genet Dev 12(1):53\u201359","journal-title":"Curr Opin Genet Dev"},{"issue":"2","key":"9376_CR27","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nrc991","volume":"3","author":"P Ch\u00e8ne","year":"2003","unstructured":"Ch\u00e8ne P (2003) Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 3(2):102\u2013109","journal-title":"Nat Rev Cancer"},{"issue":"17","key":"9376_CR28","doi-asserted-by":"publisher","first-page":"5318","DOI":"10.1158\/1078-0432.CCR-07-5136","volume":"14","author":"S Shangary","year":"2008","unstructured":"Shangary S, Wang S (2008) Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res 14(17):5318\u20135324","journal-title":"Clin Cancer Res"},{"issue":"14","key":"9376_CR29","first-page":"3918","volume":"52","author":"R Mazars","year":"1992","unstructured":"Mazars R, Spinardi L, BenCheikh M, Simony-Lafontaine J, Jeanteur P, Theillet C (1992) p53 mutations occur in aggressive breast cancer. Cancer Res 52(14):3918\u20133923","journal-title":"Cancer Res"},{"issue":"11","key":"9376_CR30","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1093\/carcin\/bgs232","volume":"33","author":"D Walerych","year":"2012","unstructured":"Walerych D, Napoli M, Collavin L, Del Sal G (2012) The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 33(11):2007\u20132017","journal-title":"Carcinogenesis"},{"issue":"16","key":"9376_CR31","doi-asserted-by":"publisher","first-page":"13595","DOI":"10.1074\/jbc.C200694200","volume":"278","author":"D Chen","year":"2003","unstructured":"Chen D, Li M, Luo J, Gu W (2003) Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. J Biol Chem 278(16):13595\u201313598","journal-title":"J Biol Chem"},{"issue":"2","key":"9376_CR32","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/jcp.20406","volume":"204","author":"AL Nieminen","year":"2005","unstructured":"Nieminen AL, Qanungo S, Schneider EA, Jiang BH, Agani FH (2005) Mdm2 and HIF-1alpha interaction in tumor cells during hypoxia. J Cell Physiol 204(2):364\u2013369","journal-title":"J Cell Physiol"},{"issue":"2","key":"9376_CR33","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1158\/0008-5472.CAN-06-2710","volume":"67","author":"GA LaRusch","year":"2007","unstructured":"LaRusch GA, Jackson MW, Dunbar JD, Warren RS, Donner DB, Mayo LD (2007) Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2. Cancer Res 67(2):450\u2013454","journal-title":"Cancer Res"},{"issue":"10","key":"9376_CR34","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1093\/carcin\/bgp196","volume":"30","author":"YM Lee","year":"2009","unstructured":"Lee YM, Lim JH, Chun YS, Moon HE, Lee MK, Huang LE, Park JW (2009) Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1alpha. Carcinogenesis 30(10):1768\u20131775","journal-title":"Carcinogenesis"},{"issue":"3","key":"9376_CR35","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10456-011-9210-8","volume":"14","author":"DM Patterson","year":"2011","unstructured":"Patterson DM, Gao D, Trahan DN, Johnson BA, Ludwig A, Barbieri E, Chen Z, Diaz-Miron J, Vassilev L, Shohet JM, Kim ES (2011) Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma. Angiogenesis 14(3):255\u2013266","journal-title":"Angiogenesis"},{"issue":"5","key":"9376_CR36","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1074\/jbc.271.5.2746","volume":"271","author":"AP Levy","year":"1996","unstructured":"Levy AP, Levy NS, Goldberg MA (1996) Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem 271(5):2746\u20132753","journal-title":"J Biol Chem"},{"issue":"3","key":"9376_CR37","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1074\/jbc.274.3.1359","volume":"274","author":"SC Shih","year":"1999","unstructured":"Shih SC, Claffey KP (1999) Regulation of human vascular endothelial growth factor mRNA stability in hypoxia by heterogeneous nuclear ribonucleoprotein L. J Biol Chem 274(3):1359\u20131365","journal-title":"J Biol Chem"},{"issue":"16","key":"9376_CR38","doi-asserted-by":"publisher","first-page":"13635","DOI":"10.1074\/jbc.M108703200","volume":"277","author":"I Goldberg-Cohen","year":"2002","unstructured":"Goldberg-Cohen I, Furneauxb H, Levy AP (2002) A 40-bp RNA element that mediates stabilization of vascular endothelial growth factor mRNA by HuR. J Biol Chem 277(16):13635\u201313640","journal-title":"J Biol Chem"},{"issue":"2","key":"9376_CR39","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1128\/MCB.02078-06","volume":"28","author":"F Vumbaca","year":"2008","unstructured":"Vumbaca F, Phoenix KN, Rodriguez-Pinto D, Han DK, Claffey KP (2008) Double-stranded RNA-binding protein regulates vascular endothelial growth factor mRNA stability, translation, and breast cancer angiogenesis. Mol Cell Biol 28(2):772\u2013783","journal-title":"Mol Cell Biol"},{"issue":"2","key":"9376_CR40","doi-asserted-by":"publisher","first-page":"R37","DOI":"10.1186\/bcr2088","volume":"10","author":"A Tordai","year":"2008","unstructured":"Tordai A, Wang J, Andre F, Liedtke C, Yan K, Sotiriou C, Hortobagyi GN, Symmans WF, Pusztai L (2008) Evaluation of biological pathways involved in chemotherapy response in breast cancer. Breast Cancer Res 10(2):R37","journal-title":"Breast Cancer Res"},{"issue":"23","key":"9376_CR41","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1038\/onc.2012.299","volume":"32","author":"X Lu","year":"2013","unstructured":"Lu X, Liu DP, Xu Y (2013) The gain of function of p53 cancer mutant in promoting mammary tumorigenesis. Oncogene 32(23):2900\u20132906","journal-title":"Oncogene"}],"updated-by":[{"DOI":"10.1007\/s10456-025-10009-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000}}],"container-title":["Angiogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-013-9376-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10456-013-9376-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-013-9376-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-013-9376-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:08:54Z","timestamp":1760612934000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10456-013-9376-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,2]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["9376"],"URL":"https:\/\/doi.org\/10.1007\/s10456-013-9376-3","relation":{},"ISSN":["0969-6970","1573-7209"],"issn-type":[{"value":"0969-6970","type":"print"},{"value":"1573-7209","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,2]]},"assertion":[{"value":"19 March 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised:  Figures 2, 7 and 8 are corrected.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10456-025-10009-5","URL":"https:\/\/doi.org\/10.1007\/s10456-025-10009-5","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}